AI Stock Analysis - Recursion Pharmaceuticals (RXRX)
Analysis generated November 18, 2025.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that utilizes machine learning and high-throughput biology to accelerate its drug discovery processes. The company's platform, called the Recursion Operating System (Recursion OS), integrates biological science with machine learning and automation to enhance drug discovery and development. By merging data-rich biology with computational science, Recursion aims to identify novel drug candidates more efficiently and potentially bring treatments to market faster than traditional methods.
Stock Alerts - Recursion Pharmaceuticals (RXRX)
 |
Recursion Pharmaceuticals | January 23 Insider Alert: Gibson Christopher is continuing selling shares |
|
Recursion Pharmaceuticals | January 22 Price is up by 6.1% in the last 24h. |
|
Recursion Pharmaceuticals | January 12 Price is up by 6% in the last 24h. |
|
Recursion Pharmaceuticals | January 9 Insider Alert: Borgeson Blake is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Recursion Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 48 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 46,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 18 | Sign up | Sign up | Sign up |
| Facebook Followers | 933 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 155 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,614 | Sign up | Sign up | Sign up |
| X Followers | 16,429 | Sign up | Sign up | Sign up |
| X Mentions | 21 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 80,800 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 41 | Sign up | Sign up | Sign up |
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
| Price | $4.73 |
| Target Price | Sign up |
| Volume | 15,840,000 |
| Market Cap | $2.59B |
| Year Range | $3.85 - $6.79 |
| Dividend Yield | 0% |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference TranscriptJanuary 21 - SeekingAlpha |
|
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case TheoryJanuary 20 - Yahoo Entertainment |
|
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment ProspectsJanuary 18 - Yahoo Entertainment |
|
 |
Recursion Pharmaceuticals: Stock Unresponsive To Clinical UpdatesJanuary 15 - SeekingAlpha |
 |
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 13 - SeekingAlpha |
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business UpdatesJanuary 7 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 5.2M | 30M | -24M | -162M | -141M | -0.360 |
| Q2 '25 | 19M | 20M | -1.1M | -172M | -148M | -0.410 |
| Q1 '25 | 15M | 22M | -7.1M | -202M | -183M | -0.500 |
| Q4 '24 | 4.5M | 13M | -8.3M | -179M | -165M | -0.530 |
| Q3 '24 | 26M | 12M | 14M | -96M | -88M | -0.340 |
Insider Transactions View All
| Gibson Christopher filed to sell 913,839 shares at $4.5. January 22 '26 |
| Borgeson Blake filed to sell 6,649,863 shares at $4.4. January 8 '26 |
| Gibson Christopher filed to sell 933,839 shares at $4.3. January 7 '26 |
| Taylor Ben R filed to sell 761,550 shares at $4.2. December 30 '25 |
| Khan Najat filed to sell 611,135 shares at $4.4. December 29 '25 |
Similar companies
Read more about Recursion Pharmaceuticals (RXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews & business outlook.
FAQ - Recursion Pharmaceuticals
The Market Cap of Recursion Pharmaceuticals is $2.59B.
Currently, the price of one share of Recursion Pharmaceuticals stock is $4.73.
The RXRX stock price chart above provides a comprehensive visual representation of Recursion Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Recursion Pharmaceuticals shares. Our platform offers an up-to-date RXRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Recursion Pharmaceuticals (RXRX) does not offer dividends to its shareholders. Investors interested in Recursion Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Recursion Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
